|
|
Béatrice Breart, Fabrice Lemaître, Susanna Celli, Philippe Bousso
J Clin Invest. 2008;
118(4):1390
doi:10.1172/JCI34388
Abstract |
Full text
| PDF
| Supplemental material

C
TLs have the potential to attack tumors, and adoptive transfer of CTLs can lead to tumor regression in mouse models and human clinical settings. However, the dynamics of tumor cell elimination during efficient T cell therapy is unknown, and it is unclear whether CTLs act directly by destroying tumor cells or indirectly by initiating the recruitment of innate immune cells that mediate tumor damage. To address these questions, we report real-time imaging of tumor cell apoptosis in vivo using intravital 2-photon microscopy and a Förster resonance energy transfer–based (FRET-based) reporter of caspase 3 activity. In a mouse model of solid tumor, we found that tumor regression after transfer of in vitro–activated CTLs occurred primarily through the direct action of CTLs on each individual tumor cell, with a minimal bystander effect. Surprisingly, the killing of 1 target cell by an individual CTL took an extended period of time, 6 hours on average, which suggested that the slow rate of killing intrinsically limits the efficiency of antitumor T cell responses. The ability to visualize when, where, and how tumor cells are killed in vivo offers new perspectives for understanding how immune effectors survey cancer cells and how local tumor microenvironments may subvert immune responses.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(46)
| Title and authors |
Publication |
Year |
An outsider's perspective—ecotaxis revisited: an integrative review of cancer environment, iron and immune system cells
Maria de Sousa
|
Integr. Biol.
|
2011 |
Intravital microscopy as a tool to study drug delivery in preclinical studies
Panomwat Amornphimoltham, Andrius Masedunskas, Roberto Weigert
|
Advanced Drug Delivery Reviews
|
2011 |
Reporting from the Field: Genetically Encoded Fluorescent Reporters Uncover Signaling Dynamics in Living Biological Systems
Sohum Mehta, Jin Zhang
|
Annu. Rev. Biochem.
|
2011 |
Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable
David Hassin, Orit G. Garber, Avihai Meiraz, Yael S. Schiffenbauer, Gideon Berke
|
Immunology
|
2011 |
Innate Immune Cells in Breast Cancer – From Villains to Heroes?
Tim Kees, Mikala Egeblad
|
J Mammary Gland Biol Neoplasia
|
2011 |
Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy
Susanna Celli, Matthew L Albert, Philippe Bousso
|
Nat Med
|
2011 |
Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment
Bettina Weigelin, Marina Krause, Peter Friedl
|
Immunology Letters
|
2011 |
High-resolution, noninvasive longitudinal live imaging of immune responses
M. H. Abdulreda, G. Faleo, R. D. Molano, M. Lopez-Cabezas, J. Molina, Y. Tan, O. A. R. Echeverria, E. Zahr-Akrawi, R. Rodriguez-Diaz, P. K. Edlund, I. Leibiger, A. L. Bayer, V. Perez, C. Ricordi, A. Caicedo, A. Pileggi, P.-O. Berggren
|
Proceedings of the National Academy of Sciences
|
2011 |
Imaging techniques for assaying lymphocyte activation in action
Lakshmi Balagopalan, Eilon Sherman, Valarie A. Barr, Lawrence E. Samelson
|
Nat Rev Immunol
|
2011 |
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells
Daniel T. Fisher, Qing Chen, Joseph J. Skitzki, Jason B. Muhitch, Lei Zhou, Michelle M. Appenheimer, Trupti D. Vardam, Emily L. Weis, Jessica Passanese, Wan-Chao Wang
|
J. Clin. Invest.
|
2011 |
|